Paratek Pharmaceuticals, Inc.
PRTK
PRTK was delisted on the 20th of September, 2023.
91 hedge funds and large institutions have $98.5M invested in Paratek Pharmaceuticals, Inc. in 2019 Q3 according to their latest regulatory filings, with 14 funds opening new positions, 32 increasing their positions, 21 reducing their positions, and 11 closing their positions.
91% more call options, than puts
Call options by funds: $514K | Put options by funds: $269K
52% more repeat investments, than reductions
Existing positions increased: 32 | Existing positions reduced: 21
27% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 11
2% more funds holding
Funds holding: 89 → 91 (+2)
4% more capital invested
Capital invested by funds: $95.1M → $98.5M (+$3.36M)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IAM
ICM Asset Management
Spokane,
Washington
|
+$1.14M |
| 2 |
GAI
General American Investors
New York
|
+$1.12M |
| 3 |
JGC
J. Goldman & Co
New York
|
+$634K |
| 4 |
Goldman Sachs
New York
|
+$371K |
| 5 |
BlackRock
New York
|
+$368K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$3.62M |
| 2 |
WIC
Water Island Capital
New York
|
-$1.52M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$1.02M |
| 4 |
FI
Fosun International
Hong Kong,
China
|
-$875K |
| 5 |
Renaissance Technologies
New York
|
-$499K |
PRTK Hedge Fund Activity: Q3 2019 in Review
91 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Paratek Pharmaceuticals, Inc. (PRTK) for Q3 2019, worth a combined $98.5M — up 3.5% from $95.1M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new PRTK positions and 11 closed out — a net gain of 3 holders — while 32 added to existing stakes and 21 trimmed.
The largest buyer was ICM Asset Management, opening a new position worth an estimated $1.14M. The largest seller was Armistice Capital, cutting an estimated $3.62M.
- 91 institutional investors held Paratek Pharmaceuticals, Inc. (PRTK) as of Q3 2019, up from 89 in Q2 2019.
- Funds reported $98.5M of Paratek Pharmaceuticals, Inc. stock for Q3 2019, up 3.5% quarter-over-quarter.
- 14 funds opened new Paratek Pharmaceuticals, Inc. positions in Q3 2019 and 11 closed out, a net change of +3 holders.
- The largest Paratek Pharmaceuticals, Inc. buyer in Q3 2019 was ICM Asset Management, an estimated $1.14M added.
- The largest Paratek Pharmaceuticals, Inc. seller in Q3 2019 was Armistice Capital, an estimated $3.62M sold.
Based on aggregated 13F filings for Q3 2019.